

# PharmEasy - Investor Note

PharmEasy is a consumer healthcare super app offering home delivery of prescription and OTC medicines, diagnostic tests, and teleconsultations.

Market Cap	FY25 Total Income	FY25 EBITDA	FY25 PAT
₹11,000 Crore	₹5,980 Crore	-₹553.5 Crore	-₹1,572 Crore

## Business and Financial Highlights

- Multiple Levers for Value Creation**  
API's diversified assets across pharma retail, diagnostics, B2B distribution, and tech provide multiple growth levers -diagnostics, subscriptions, telemedicine, and offline expansion
- Strategic Acquisitions**  
The company has expanded through acquisitions like Medlife and a 66.1% stake in Thyrocare, strengthening its position as an integrated healthcare provider.
- Clear Focus on Margin Improvement and Path to Profitability**  
Company disclosures show management is reducing burn, optimising costs, and targeting higher EBITDA margins, following a value-unlocking path seen in earlier high-growth platforms.

## Recent Financial Performance

